FY2025 · ended Dec 31, 2025 · Revenue $14.25B, -3.0% YoY · Filed Feb 26, 2026
Viatris Inc. (VTRS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $14.3 billion and a net loss of $3.5 billion. Free cash flow was $1.9 billion. As of Jun 30, 2026 it held $886.5 million in cash and investments and $13.6 billion in total debt.
Revenue (TTM)
$14.69B
+4.5% vs year-ago TTM
Net income
$-3.51B
-454.2% vs prior year
Operating cash flow (TTM)
$2.33B
+12.9% vs year-ago TTM
Free cash flow (TTM)
$1.95B
+11.6% vs year-ago TTM
EPS
$-3.00
-466.0% vs prior year
Dividend per share (TTM)
$0.48
+0.0% vs year-ago TTM
Shares outstanding
1.15B
-2.9% vs prior year
Net cash
$-12.74B
as of Jun 30, 2026
Operating margin
-0.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VTRS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Canonsburg, PA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1792044
- Former names
- Upjohn Inc (until Nov 10, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $14.3B | $14.7B | $15.4B | $16.2B | $17.8B |
| Operating income | -$2.7B | $10.1M | $766.2M | $1.6B | -$34.0M |
| Net income | -$3.5B | -$634.2M | $54.7M | $2.1B | -$1.3B |
| Diluted EPS | -$3.00 | -$0.53 | $0.05 | $1.71 | -$1.05 |
| Operating cash flow | $2.3B | $2.3B | $2.9B | $3.0B | $3.0B |
| Free cash flow | $1.9B | $2.0B | $2.5B | $2.6B | $2.6B |
| Total assets | $37.2B | $41.5B | $47.7B | $50.0B | $54.8B |
| Total liabilities | $22.5B | $22.9B | $27.2B | $28.9B | $34.4B |
| Stockholders' equity | $14.7B | $18.6B | $20.5B | $21.1B | $20.5B |
| Cash and investments | $1.4B | $772.8M | $1.0B | $1.3B | $739.4M |
| Total debt | $14.7B | $14.3B | $18.4B | $19.5B | $23.4B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Other events
|
Oct 8, 2026 | Oct 8, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 1, 2026 | Jul 1, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jun 18, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Other events
|
Jun 15, 2026 | Jun 12, 2026 |
All 542 Viatris Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.